Aerobic Dehydrogenative Aromatization in the Preparation of 4-Aminoquinoline Derivatives by Synergistic Pd/Cu Catalysis
作者:Fei Chen、Huidan Geng、Chun Li、Jianta Wang、Bing Guo、Lei Tang、Yuan-Yong Yang
DOI:10.1021/acs.joc.3c01400
日期:2023.11.17
The 4-aminoquinoline moiety is widely present in various bioactive compounds and marketed drugs, while the preparation of this target structure relies heavily on the amination of 4-chloroquinolines. Herein, an atom and step economic procedure was developed based on an aerobic dehydrogenative aromatization strategy. Unlike the well-known palladium-catalyzed dehydrogenative aromatization of cyclohexanones
4-氨基喹啉部分广泛存在于各种生物活性化合物和市售药物中,而该目标结构的制备很大程度上依赖于4-氯喹啉的胺化。在此,基于有氧脱氢芳构化策略开发了原子和步骤经济程序。与众所周知的钯催化环己酮与胺的脱氢芳构化不同,协同 Pd/Cu 催化对于 2,3-二氢喹啉-4(1 H )-one 类型的底物至关重要。在优化条件下,一系列芳香族/脂肪族胺和2,3-二氢喹啉-4(1H ) -酮偶联,以中等到高收率得到相应的4-氨基喹啉产物,并应用当前的方法还展示了上市药物的制备和后期多样化。
Fused, tricyclic sulfonamide inhibitors of gamma secretase
申请人:Elan Pharmaceuticals Inc.
公开号:EP2450358A1
公开(公告)日:2012-05-09
The invention provides compounds of formula I:
or pharmaceutically salts thereof, where R1, R2 and the A, B, and C-rings are as defined herein. Compounds of formula I are useful in treating or preventing cognitive disorders, such as Alzheimer's disease. The invention also encompasses pharmaceutical compositions comprising compounds or salts of formula I, methods of preparing the desired compunds, and methods of treating cognitive disorders, such as Alzheimer's disease, using the compounds or salts of formula I.
本发明提供了式 I 的化合物:
或其药用盐,其中 R1、R2 和 A、B 及 C 环如本文所定义。式 I 的化合物可用于治疗或预防认知障碍,如阿尔茨海默病。本发明还包括包含式 I 化合物或盐的药物组合物、制备所需组合物的方法以及使用式 I 化合物或盐治疗认知障碍(如阿尔茨海默病)的方法。
Cyclization products of N-fluorophenyl-β-alanines and their properties
作者:R. Vaickelioniene、V. Mickevicius
DOI:10.1007/s10593-006-0157-4
日期:2006.6
DISUBSTITUIERTE BICYCLISCHE HETEROCYCLEN, IHRE HERSTELLUNG UND IHRE VERWENDUNG ALS ARZNEIMITTEL
申请人:Boehringer Ingelheim Pharma GmbH & Co.KG
公开号:EP0966454B1
公开(公告)日:2003-05-07
FUSED, TRICYCLIC SULFONAMIDE INHIBITORS OF GAMMA SECRETASE